Media.Player

USA Patent Application '61/219,073: Materials and Methods for Prevention and Treatment of Viral Infections.

Summary

1、 等离子点火系统中：
等离子喷枪采用目前国际先进的管状等离子发生器，它属于旋气稳定压缩的等离子发生器。从热效率角度看，管弧等离子发生器比同轴磁稳式等离子发生器的热效率高10%左右，管状电弧加热器的电极烧损率低、电极寿命长、气流污染小。
供电装置采用IGBT晶体管整流电源，功率因数可以达到0.95以上，最大限度减少电网中的无功功率，同时最大程度的减少对电网的谐波干扰。煤粉燃烧器采用多级浓缩方式。各级浓缩器之间的距离可以进行调整，从而保证了煤粉的浓缩效果，达到等离子点火最合适的煤粉浓度。
等离子喷枪与煤粉燃烧器同轴，保证等离子喷枪电弧火焰与煤粉运动具有相同的轴向方向，同时还能够卷吸煤粉，使等离子喷枪电弧火焰与煤粉能够进行良好的接触，从而能够保证成功点燃煤粉与稳定燃烧；煤粉点火燃烧器为双层燃烧室结构，使一部分淡风粉气流从空隙流出，冷却煤粉燃烧器外喷口，从而防止了煤粉燃烧器的结焦问题。
2、双螺旋气动雾化微油点火系统：
双螺旋气动雾化微油枪，雾化方式采用双螺旋气动二次雾化，雾化后的油雾同时具有轴向前进速度与切向环绕速度，能够卷吸助燃风，与助燃风进行充分混合，达到完全燃烧。
煤粉点火燃烧器采用多级浓缩与分级燃烧技术，由燃烧器碰撞浓缩块与燃烧器碰撞浓缩环组成，对一次风粉混合物进行高效率的浓缩，浓缩器与浓缩环均采用锥形的结构，燃烧器喷口采用同心结构的两圆筒结构，保证煤粉点燃以后的加热扩张能力。
双螺旋气动雾化微油枪与煤粉燃烧器同轴，从而保证微油枪燃烧火焰与煤粉运动具有相同的轴向方向，同时也能够卷吸煤粉，微油枪燃烧火焰与煤粉能够进行良好的接触，从而保证成功点燃煤粉与稳定燃烧。
煤粉点火燃烧器为双层燃烧室结构，使一部分淡风粉气流从空隙流出，冷却煤粉燃烧器外喷口，从而防止了煤粉燃烧器的结焦问题。
点火应用范围覆盖褐煤、烟煤、贫煤、无烟煤、混煤等各种煤种的煤粉，以及石油焦等燃料，可以广泛应用于电力、石化、冶金等各种不同行业的煤粉锅炉。
知识产权状况及获奖情况：
1、授权发明专利：双螺旋气动雾化微油点火与稳燃装置系统
（专利号：ZL200910082682.4）
2、实用新型专利：带有氧气助燃装置的双强化微油点火与稳燃装置系统（专利号：ZL200920278136.3）
3、实用新型专利：新型等离子电弧点火装置系统
（专利号：ZL200720176167.9）。
4 、发明专利：采用IGBT晶体管整流供电的等离子点火装置
(专利号：ZL2013102889133.3 )

Supplementary Information

Patent Number: US20130029923A1
Application Number: US13519640A
Inventor: Lau, Allan Sik-Yin | Yang, Lai Hung Cindy | Law, Anna Hing-Yee
Priority Date: 30 Dec 2009
Priority Number: US20130029923A1
Application Date: 10 Oct 2012
Publication Date: 31 Jan 2013
IPC Current: A61K00317034 | A61K003119 | A61K0031215 | A61P003112 | A61P003116 | C07C005742 | C07C006976 | C07H001500 | C07H001506
US Class: 514025 | 514531 | 514570 | 5360041 | 5360182 | 560104 | 562496
Title: Materials and Methods for Prevention and Treatment of Viral Infections
Usefulness: Materials and Methods for Prevention and Treatment of Viral Infections
Summary: The therapeutic composition is used for preventing and/or treating viral infection caused by influenza virus A, B, or C; infection caused by virus selected from H1N1, H9N2, H3N2, H5N1, H2N2, H7N7, or H7N1; or infection caused by virus selected from H1N1 (A/HK/54/98, oseltamivir-sensitive strain), H1N1 (A/Vicotria/07159200/07, oseltamivir-resistant strain), H9N2 (A/Quail/HK/G1/97), H3N2 (A/H3N2/1174/99), H5N1(A/H5N1/97), H1N1 (A/54/98), H9N2/G1, or H6N1 (A/Teal/HK/W312/97) in human (all claimed), apes, chimpanzees, orangutans, humans, monkeys, and domesticated animals, e.g. dogs, cats, horses, cattle, pigs, sheep, goats, chickens, mice, rats, guinea pigs, and hamsters. Influenza A virus includes any of the strains of H1N1, H1N2, H1N3, H1N4, H1N5, H1N6, H1N7, H1N8, H1N9, H2N1, H2N2, H2N3, H2N4, H2N5, H2N6, H2N7, H2NS, H2N9, H3N1, H3N2, H3N3, H3N4, H3N5, H3N6, H3N7, H3N8, H3N9, H4N1, H5N2, H5N3, H5N4, H5N5, H5N6, H5N7, H5N8, H5N9, H6N1, H6N2, H6N3, H6N4, H6N5, H6N6, H6N7, H6N8, H6N9, H7N1, H7N2, H7N3, H7N4, H7N5, H7N6, H7N7, H7N8, H7N9, H8N1, H8N2, H8N3, H8N4, H8N5, H8N6, H8N7, H8N8, H8N9, H9N1, H9N2, H9N3, H9N4, H9N5, H9N6, H9N7, H9N8, H9N9, H10N1, H10N2, H10N3, H10N4, H10N5, H10N6, H10N7, H10N8, H10N8, H10N9, H11N1, H11N2, H11N3, H11N4, H11N5, H11N6, H11N7, H11N8, H11N9, H12N1, H12N2, H12N3, H12N4, H12N5, H12N6, H12N7, H12N8, H12N9, H13N1, H13N2, H13N3, H13N4, H13N5, H13N6, H13N7, H13N8, H13N9, H14N1, H14N2, H14N3, H14N4, H14N5, H14N6, H14N7, H14N8, H14N9, H15N1, H15N2, H15N3, H15N4, H15N5, H15N6, H15N7, H15N8, and H15N9. The composition is used for preventing, treating, or ameliorating infections caused by viruses including respiratory syncytial virus, rhinovirus, HIV virus, hepatitis viruses including hepatitis A, B, C, D, E, F, and G virus, oncoviruses, human papilloma virus, human T-lymphotropic virus type I, bovine leukemia virus, Epstein-Barr virus, herpes simplex virus 1, herpes simplex virus 2, coronavirus, and poliovirus. The composition is used for treating neuralgia or neurasthenia associated with herpes zoster reactivation, i.e. shingles; and chronic fatigue syndrome caused by viral infections. It is used for preventing, treating, or ameliorating infections caused by pathogens including bacteria, fungi, parasitic microorganisms, RNA, DNA, retroviral vectors, tumor/oncogenic viruses, prions, protozoa, and/or environmental toxins. To determine the inhibitory effects of forsythoside A on viruses, Madin-Darby canine kidney (MDCK) cells were infected with human influenza viruses, and viral titer 50% tissue culture infective dose bioassay was performed. The test result revealed that viral replication in MDCK cells was suppressed by forsythoside A at 100 μ g/ml. Specifically, the replication of influenza viruses H1N1 (A/HK/54/98), H1N1 (A/Vicotria/07159200/07) (H1N1-R), H9N2 (A/Quail/HK/G1/97), and H3N2 (A/H3N2/1174/99) was suppressed by forsythoside A for 15-, 3-, 24-, and 12-fold, respectively, when compared with dimethylsulfoxide-treated cells.
Novelty: Therapeutic composition used for preventing and/or treating e.g. HIV virus infection comprises isolated compound selected from methoxytetrahydropyran compound, phenylpropenone compound, phenyl compound, and/or ester compound

Industry

Disease Diagnostic/Treatment

Sub Category

HIV

Application No.

1. 授权发明专利：双螺旋气动雾化微油点火与稳燃装置系统
（专利号：ZL200910082682.4）
2. 实用新型专利：带有氧气助燃装置的双强化微油点火与稳燃装置系统（专利号：ZL200920278136.3）
3. 实用新型专利：新型等离子电弧点火装置系统
（专利号：ZL200720176167.9）。
4 . 发明专利：采用IGBT晶体管整流供电的等离子点火装置
(专利号：ZL2013102889133.3 )

Country/Region

Hong Kong